Home > Press > TenasiTech secures additional $509,000 funding to bring scratch resistant acrylics to the world
Abstract:
TenasiTech has been awarded a major grant from the Australian Government to bring its nano-additives for acrylic glass to the global market.
As a recipient of support under the Australian Government’s Accelerating Commercialisation program, TenasiTech will receive AU$509,000 to complete the marketing phase of its radical approach to toughen the surface of acrylic glass.
CEO, Richard Marshall, said, “We are thrilled by the support offered by this grant. Companies are showing strong interest in having more durable, glossy surfaces inside cars, around computer screens and in the many other uses for acrylic glass. This is something we offer in a simpler and cheaper way than the current coating techniques.”
TenasiTech has developed an additive product, SOLID-TT™, for acrylic glass to withstand scratching and maintain its glossy appearance. The poor scratch resistance of acrylic glass is a key barrier to the more widespread replacement of traditional glass.
Mr Marshall added, “We offer a solution which is safe, easy to incorporate and cheaper for manufacturers of acrylic sheets and injection molded parts. What’s more, our solution allows more design options to our customers, as the plastic can be shaped and bent unlike our competitors.”
TenasiTech operates globally, with facilities in Australia and the US. The company owns and controls a number of patent applications and granted patents.
####
About TenasiTech
TenasiTech is a materials company making plastics perform at levels not thought possible – at industrial cost – selling nanotechnology additives. One product dramatically improves the scratch resistance of acrylic sheets and molded products (PMMA). Unlike competitors, we allow users to reshape the resulting acrylic. We also sell a product range, our Adaptive Polyols™, to improve thermoplastic polyurethanes (TPUs), specifically toughness or operating temperature. These improvements are made with no trade-off in the material’s clarity or flexibility. TenasiTech has operations in Boston, USA and Brisbane, Australia, and has manufacturing capability in the USA, Germany and Australia. The underlying patented technology was developed at The University of Queensland and was licensed from UniQuest, the main technology transfer company at The University of Queensland, to TenasiTech in 2007. Subsequently, the company secured investment from Uniseed Ventures, an Australian seed stage investor, and most recently from angel investors from Brisbane and Melbourne Angels.
For more information, please click here
Contacts:
Richard Marshall
Phone: 5185725827
Fax: 5185725827
Copyright © TenasiTech
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Materials/Metamaterials/Magnetoresistance
Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024
Focused ion beam technology: A single tool for a wide range of applications January 12th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||